ANDA 40265, held by Fresenius Kabi USA. Methotrexate Sodium.
As of Nov 19, 2026, ANDA 40265 (Methotrexate Preservative Free), held by Fresenius Kabi USA, was first approved by FDA on Feb 26, 1999, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 26, 1999 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate Preservative FreeEQ 25MG BASE/ML · injectable;injection | Methotrexate Sodium | Discontinued |
| Mar 3, 2017 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 2, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Oct 16, 2001 | Supplement 5Labeling | Approved | None posted |
| Oct 16, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Oct 16, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Oct 16, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Feb 17, 2000 | Supplement 1Manufacturing | Approved | None posted |
| Feb 26, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters